Molecular modeling of the human vasopressin V2 receptor/agonist complex

被引:36
|
作者
Czaplewski, C [1 ]
Kazmierkiewicz, R [1 ]
Ciarkowski, J [1 ]
机构
[1] Univ Gdansk, Fac Chem, PL-80952 Gdansk, Poland
关键词
AMBER; 4.1; constrained simulated annealing; GPCR; molecular dynamics; receptor-agonist interaction; vasopressin V2 receptor;
D O I
10.1023/A:1007969526447
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The V2 vasopressin renal receptor (V2R), which controls antidiuresis in mammals, is a member of the large family of heptahelical transmembrane (7TM) G protein-coupled receptors (GPCRs). Using the automated GPCR modeling facility available via Internet (http://expasy.hcuge.ch/swissmod/SWISS-MODEL.html) for construction of the 7TM domain in accord with the bovine rhodopsin (RD) footprint, and the SYBYL software for addition of the intra- and extracellular domains, the human V2R was modeled. The structure was further refined and its conformational variability tested by the use of a version of the Constrained Simulated Annealing (CSA) protocol developed in this laboratory An inspection of the resulting structure reveals that the V2R (likewise any GPCR modeled this way) is much thicker and accordingly forms a more spacious TM cavity than most of the hitherto modeled GPCR constructs do, typically based on the structure of bacteriorhodopsin (BRD). Moreover, in this model the 7TM helices are arranged differently than they are in any BRD-based model. Thus, the topology and geometry of the TM cavity, potentially capable of receiving Ligands, is in this model quite different than it is in the earlier models. In the subsequent step, two ligands, the native [arginines] vasopressin (AVP) and the selective agonist [D-arginine(8)]vasopressin (DAVP) were inserted, each in two topologically non-equivalent ways, into the TM cavity and the resulting structures were equilibrated and their conformational variabilities tested using CSA as above. The best docking was selected and justified upon consideration of ligand-receptor interactions and structure-activity data. Finally, the amino acid residues were indicated, mainly in TM helices 3-7, as potentially important in both AVP and DAVP docking. Among those Cys(112), Val(115)-Lys(116), Gln(119), Met(123) in helix 3; Glu(174) in helix 4; Val(206), Ala(210), Val(213)-Phe(214) in helix 5; Trp(284), Phe(287)-Phe(288), Gln(291) in helix 6; and Phe(307), Leu(310), Ala(314) and Asn(317) in helix 7 appeared to be the most important ones. Many of these residues are invariant for either the GPCR superfamily or the neurophyseal (vasopressin V2R, V1aR and V1bR and oxytocin OR) subfamily of receptors. Moreover, some of the equivalent residues in V1aR have already been found critical for the ligand affinity [Mouillac et al., J. Biol. Chem, 270 (1995) 25771].
引用
收藏
页码:275 / 287
页数:13
相关论文
共 50 条
  • [1] Molecular modeling of the human vasopressin V2 receptor/agonist complex
    Cezary Czaplewski
    Rajmund Kaźmierkiewicz
    Jerzy Ciarkowski
    Journal of Computer-Aided Molecular Design, 1998, 12 : 275 - 287
  • [2] Agonist and antagonist-dependent internalization of the human vasopressin V2 receptor
    Pfeiffer, R
    Kirsch, J
    Fahrenholz, F
    EXPERIMENTAL CELL RESEARCH, 1998, 244 (01) : 327 - 339
  • [3] Molecular modeling of Vasopressin V2 Receptor tetramer in hydrated lipid membrane
    Witt, Magdalena
    Slusarz, Magdalena J.
    Ciarkowski, Jerzy
    QSAR & COMBINATORIAL SCIENCE, 2008, 27 (06): : 684 - 693
  • [4] Molecular basis of ligand recognition and activation of human V2 vasopressin receptor
    Zhou, Fulai
    Ye, Chenyu
    Ma, Xiaomin
    Yin, Wanchao
    Croll, Tristan I.
    Zhou, Qingtong
    He, Xinheng
    Zhang, Xiaokang
    Yang, Dehua
    Wang, Peiyi
    Xu, H. Eric
    Wang, Ming-Wei
    Jiang, Yi
    CELL RESEARCH, 2021, 31 (08) : 929 - 931
  • [5] Molecular basis of ligand recognition and activation of human V2 vasopressin receptor
    Fulai Zhou
    Chenyu Ye
    Xiaomin Ma
    Wanchao Yin
    Tristan I. Croll
    Qingtong Zhou
    Xinheng He
    Xiaokang Zhang
    Dehua Yang
    Peiyi Wang
    H. Eric Xu
    Ming-Wei Wang
    Yi Jiang
    Cell Research, 2021, 31 : 929 - 931
  • [6] Constitutive internalisation of the human V2 vasopressin receptor
    Hermosilla, R
    Schmidt, A
    Schwieger, I
    Oksche, A
    Schülein, R
    Wiesner, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R18 - R19
  • [7] Constitutive internalisation of the human V2 vasopressin receptor
    Hermosilla, R
    Schmidt, A
    Schwieger, I
    Oksche, A
    Schülein, R
    Wiesner, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R18 - R18
  • [8] Molecular modelling of the vasopressin V2 receptor/antagonist interactions
    Czaplewski, C
    Kazmierkiewicz, R
    Ciarkowski, J
    ACTA BIOCHIMICA POLONICA, 1998, 45 (01) : 19 - 26
  • [9] Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination
    Martin, NP
    Lefkowitz, RJ
    Shenoy, SK
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) : 45954 - 45959
  • [10] Vasopressin V2 receptor antagonists
    Wong, LL
    Verbalis, JG
    CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 391 - 402